Despite recent advances in the field of HSCT, viral infections remain a frequent causeof morbidity and mortal-ity among HSCT recipients. Adoptive transfer of viral specific T cells has been successfully used both as pro-phylaxis and treatment of viral infections in immunocompromised HSCT recipients. Increasingly, precise risk stratification of HSCT recipients with infectious complications should incorporate not only pretransplant clinical criteria, but milestones of immune reconstitution as well. These factors can better identify those at highest risk of morbidity and mortality and identify a population of HSCT recipients in whom adoptive ther-apy with viral specific T cells should be considered for either prophylaxis or second line treatment early after inadequate response to first line antiviral therapy. Broadening these approaches to improve outcomes for transplant recipients in countries with limited resources is a major challenge. While the principles of risk stratification can be applied, early detection of viral reactivation as well as treatment is challenging in regions where commercial PCR assays and antiviral agents are not readily available.(c) 2022 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
File in questo prodotto:
Non ci sono file associati a questo prodotto.